OverviewSuggest Edit

Kinnate Biopharma is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. It utilizes its expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which the company refers to as the Kinnate Discovery Engine, to develop targeted therapies.

TypePublic
Founded2018
HQSan Diego, CA, US
Websitekinnate.com

Latest Updates

Employees (est.) (Sept 2020)27
Share Price (Jun 2021)$23.8(+2%)
Cybersecurity ratingAMore

Key People/Management at Kinnate Biopharma

Nima Farzan

Nima Farzan

CEO and Director
Eric Murphy

Eric Murphy

CSO
Mark Meltz

Mark Meltz

COO & General Counsel
Eric Martin

Eric Martin

SVP, Translational Medicine
Richard Williams

Richard Williams

Chief Medical Officer
Sanjeev Thohan

Sanjeev Thohan

VP, Non-Clinical Development
Show more

Kinnate Biopharma Office Locations

Kinnate Biopharma has an office in San Diego
San Diego, CA, US (HQ)
11975 El Camino Real #101
Show all (1)

Kinnate Biopharma Financials and Metrics

Kinnate Biopharma Revenue

USD

Net income (FY, 2019)

(12.0m)

EBIT (FY, 2019)

(12.0m)

Market capitalization (16-Jun-2021)

1.0b

Closing stock price (16-Jun-2021)

23.8

Cash (30-Sept-2020)

156.9m
Kinnate Biopharma's current market capitalization is $1 b.
USDFY, 2018FY, 2019

General and administrative expense

2.0m3.1m

R&D expense

5.7m9.0m

Operating expense total

7.6m12.0m

EBIT

(7.6m)(12.0m)
Annual
USDFY, 2018FY, 2019

Cash

7.0m76.5m

Accounts Receivable

1.1m973.0k

Prepaid Expenses

25.0k

Current Assets

8.1m77.5m
Quarterly
USDQ3, 2020

Cash

156.9m

Prepaid Expenses

620.0k

Current Assets

157.5m
Annual
USDFY, 2018FY, 2019

Net Income

(7.6m)(12.0m)

Accounts Payable

467.0k1.5m

Cash From Operating Activities

(8.2m)(10.5m)

Cash From Financing Activities

15.2m80.0m
Quarterly
USDQ3, 2019Q3, 2020

Net Income

(8.0m)(22.1m)

Depreciation and Amortization

59.0k

Accounts Payable

425.0k3.9m

Cash From Operating Activities

(7.2m)(16.4m)
USDFY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Kinnate Biopharma Operating Metrics

Q3, 2020

New Chemical Entities

3.3 k

Drug Metabolism and Pharmacokinetics Studies

4 k

Unique In Vitro Assays

170

In Vivo Pharmacology Studies

80
Show all operating metrics

Kinnate Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Kinnate Biopharma Online and Social Media Presence

Embed Graph

Kinnate Biopharma News and Updates

Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires

Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

SAN FRANCISCO and SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of a …

Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors

SAN FRANCISCO and SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Dr. …

Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results

Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers

Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index

SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it w…
Show more

Kinnate Biopharma Frequently Asked Questions

  • When was Kinnate Biopharma founded?

    Kinnate Biopharma was founded in 2018.

  • Who are Kinnate Biopharma key executives?

    Kinnate Biopharma's key executives are Nima Farzan, Eric Murphy and Mark Meltz.

  • How many employees does Kinnate Biopharma have?

    Kinnate Biopharma has 27 employees.

  • Who are Kinnate Biopharma competitors?

    Competitors of Kinnate Biopharma include Shorla Pharma, Felicitex Therapeutics and XNK Therapeutics.

  • Where is Kinnate Biopharma headquarters?

    Kinnate Biopharma headquarters is located at 11975 El Camino Real #101, San Diego.

  • Where are Kinnate Biopharma offices?

    Kinnate Biopharma has an office in San Diego.

  • How many offices does Kinnate Biopharma have?

    Kinnate Biopharma has 1 office.